A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PFS, OS / progression-free and overall survival

[Related PubMed/MEDLINE]
Total Number of Papers: 27
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PFS, OS  (>> Co-occurring Abbreviation)
Long Form:   progression-free and overall survival
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer. high-TB, TKI
2021 Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. MM, NRM, REL
2021 Nomograms including the controlling nutritional status score in patients with hepatocellular carcinoma undergoing transarterial chemoembolisation for prediction survival: a retrospective analysis. CONUT, HCC, TACE
2021 Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement. FET
2020 Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer. mCRC
2020 Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET. AA, FET, GBM, IDH, MGMT, MTV, TTP, WHO
2020 Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer. BL, MBC, sTK1, TK1
2019 5-Aminolevulinic Acid Fluorescence-Guided Resection of 18F-FET-PET Positive Tumor Beyond Gadolinium Enhancing Tumor Improves Survival in Glioblastoma. GBM, MRI
2019 Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. EMT, ICB, NSCLC
10  2019 Should mucosal bowel invasion in ovarian cancer be assigned to FIGO stage IV disease? EOC, IP
11  2018 The role novel targeted agents in the treatment of previously treated patients with advanced urothelial carcinoma (UC): a meta-analysis. DCR, ICIs, ORR, TAs, TKIs, UC
12  2018 Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care. HR-MDS, TFIs
13  2016 A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors. NSCLC, TKIs
14  2016 Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis. DCR, ORR, RR, UC
15  2015 Prognostic potential of initial CT changes for progression-free survival in gefitinib-treated patients with advanced adenocarcinoma of the lung: a preliminary analysis. CT, EGFR, NRC, NSCLC
16  2014 Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results. mCRC
17  2014 Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review. LFFR, RR, SCCHN
18  2014 Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab. CET, DCE-MRI, rGB, VWR
19  2014 Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma. HGSOC, IPA, URA
20  2014 Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases. SBT
21  2014 Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. RCC
22  2012 A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer. CCI, NSCLC, PDGFR, RR, VES-13
23  2012 Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). CML, pts, TKI
24  2012 Stereotactic iodine-125 brachytherapy for treatment of inoperable focal brainstem gliomas of WHO grades I and II: feasibility and long-term outcome. F-BSG, SBT, WHO
25  2010 Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. ES, HSCT, NRM
26  2009 Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. GIST, GP, IM, LP, RD, SU
27  2004 Epidemiology, clinical features and treatment outcome of Wilms' tumor in Taiwan: a report from Taiwan Pediatric Oncology Group. TPOG, WT